AbCellera Biologics Inc. (ABCL) Operating Margin
- Operating margin · 12 months: Value -340.27%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -340.27% | Operating income / revenue. Period ending 2026-06-30. $-225.16M ÷ $66.17M × 100 ≈ -340.27% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -225.16M USD | Operating Income (Loss) |
| Revenue | 66.17M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 197.77M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-225.16M | $66.17M | (m) | $197.77M | (m) | -340.27% |
| 2026-03-31 | $-211.96M | $79.21M | (m) | $191.00M | (m) | -267.60% |
| 2025-12-31 | $-217.10M | $75.13M | (m) | $186.83M | (m) | -288.98% |
| 2025-09-30 | $-261.28M | $35.33M | (m) | $182.81M | (m) | -739.63% |
| 2025-06-30 | $-278.66M | $32.88M | (m) | $168.76M | (m) | -847.62% |
| 2025-03-31 | $-322.53M | $23.11M | (m) | $170.47M | (m) | -1395.40% |
| 2024-12-31 | $-314.77M | $28.83M | (m) | $167.26M | (m) | -1091.69% |
| 2024-09-30 | $-308.06M | $32.96M | (m) | $169.81M | (m) | -934.60% |
| 2024-06-30 | $-269.29M | $33.05M | (m) | $166.75M | (m) | -814.70% |
| 2024-03-31 | $-227.23M | $35.79M | (m) | $162.30M | (m) | -634.94% |
| 2023-12-31 | $-237.21M | $38.02M | (m) | $175.66M | (m) | -623.82% |
| 2023-09-30 | $-208.93M | $50.39M | (m) | $155.28M | (m) | -414.62% |
| 2023-06-30 | $-116.31M | $145.18M | (m) | $143.95M | (m) | -80.11% |
| 2023-03-31 | $-73.31M | $181.03M | (m) | $134.16M | (m) | -40.50% |
| 2022-12-31 | $216.51M | $485.42M | (m) | $107.88M | (m) | 44.60% |
| 2022-09-30 | $335.84M | $603.21M | (m) | $96.84M | (m) | 55.68% |
| 2022-06-30 | $269.99M | $507.32M | (m) | $87.71M | (m) | 53.22% |
| 2022-03-31 | $271.29M | $489.04M | (m) | $76.08M | (m) | 55.47% |
| 2021-12-31 | $204.41M | $375.20M | (m) | $62.06M | (m) | 54.48% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $156.03M | $233.16M | (m) | $29.39M | (m) | 66.92% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-4.12M | $11.61M | (m) | $10.11M | (m) | -35.45% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |